Terril Brothers Inc. Boosts Stock Position in Eli Lilly and Company $LLY

Terril Brothers Inc. grew its position in Eli Lilly and Company (NYSE:LLY) by 8.2% during the second quarter, according to its most recent Form 13F filing with the SEC. The firm owned 703 shares of the company’s stock after purchasing an additional 53 shares during the period. Eli Lilly and Company makes up 0.2% of Terril Brothers Inc.’s holdings, making the stock its 29th largest position. Terril Brothers Inc.’s holdings in Eli Lilly and Company were worth $548,000 at the end of the most recent quarter.

Other institutional investors and hedge funds have also recently modified their holdings of the company. Pinnacle Associates Ltd. boosted its position in Eli Lilly and Company by 1.5% in the second quarter. Pinnacle Associates Ltd. now owns 54,182 shares of the company’s stock valued at $42,237,000 after buying an additional 797 shares during the last quarter. UNIVEST FINANCIAL Corp lifted its stake in Eli Lilly and Company by 54.0% during the 2nd quarter. UNIVEST FINANCIAL Corp now owns 27,619 shares of the company’s stock valued at $21,530,000 after acquiring an additional 9,681 shares during the period. Simon Quick Advisors LLC increased its stake in shares of Eli Lilly and Company by 64.0% in the second quarter. Simon Quick Advisors LLC now owns 10,018 shares of the company’s stock worth $7,809,000 after acquiring an additional 3,910 shares during the period. Ledyard National Bank raised its stake in shares of Eli Lilly and Company by 8.3% during the 2nd quarter. Ledyard National Bank now owns 4,883 shares of the company’s stock valued at $3,806,000 after buying an additional 376 shares during the last quarter. Finally, Coign Capital Advisors LLC grew its holdings in Eli Lilly and Company by 2.3% during the second quarter. Coign Capital Advisors LLC now owns 789 shares of the company’s stock worth $615,000 after acquiring an additional 18 shares during the period. Institutional investors and hedge funds own 82.53% of the company’s stock.

Analysts Set New Price Targets

A number of research analysts have issued reports on the company. Morgan Stanley decreased their price target on Eli Lilly and Company from $1,028.00 to $1,023.00 and set an “overweight” rating for the company in a report on Friday, October 3rd. The Goldman Sachs Group upped their price target on Eli Lilly and Company from $876.00 to $879.00 and gave the stock a “buy” rating in a report on Friday, October 10th. Leerink Partners reaffirmed a “market perform” rating and set a $715.00 target price on shares of Eli Lilly and Company in a research note on Thursday, August 7th. Weiss Ratings reissued a “hold (c+)” rating on shares of Eli Lilly and Company in a research note on Wednesday, October 8th. Finally, JPMorgan Chase & Co. reduced their price objective on shares of Eli Lilly and Company from $1,100.00 to $1,050.00 and set an “overweight” rating for the company in a research report on Tuesday, September 16th. One investment analyst has rated the stock with a Strong Buy rating, fourteen have issued a Buy rating and nine have issued a Hold rating to the company’s stock. According to MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and a consensus price target of $936.47.

Insider Activity at Eli Lilly and Company

In other news, Director J Erik Fyrwald acquired 1,565 shares of the business’s stock in a transaction that occurred on Tuesday, August 12th. The shares were purchased at an average price of $642.33 per share, for a total transaction of $1,005,246.45. Following the acquisition, the director owned 74,578 shares of the company’s stock, valued at $47,903,686.74. This represents a 2.14% increase in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Also, EVP Daniel Skovronsky bought 1,000 shares of the stock in a transaction that occurred on Tuesday, August 12th. The shares were purchased at an average price of $634.40 per share, with a total value of $634,400.00. Following the completion of the acquisition, the executive vice president directly owned 137,660 shares in the company, valued at $87,331,504. This trade represents a 0.73% increase in their ownership of the stock. The disclosure for this purchase is available in the SEC filing. Insiders acquired 4,514 shares of company stock valued at $2,894,841 over the last ninety days. 0.13% of the stock is owned by insiders.

Eli Lilly and Company Trading Up 3.5%

Shares of Eli Lilly and Company stock opened at $842.28 on Friday. Eli Lilly and Company has a 1-year low of $623.78 and a 1-year high of $935.63. The company has a debt-to-equity ratio of 1.86, a current ratio of 1.28 and a quick ratio of 1.00. The stock has a market cap of $797.18 billion, a P/E ratio of 55.05, a P/E/G ratio of 1.21 and a beta of 0.47. The stock’s 50 day simple moving average is $777.69 and its 200-day simple moving average is $770.84.

Eli Lilly and Company (NYSE:LLY) last issued its earnings results on Thursday, October 30th. The company reported $7.02 earnings per share (EPS) for the quarter, beating the consensus estimate of $6.42 by $0.60. The company had revenue of $17.60 billion during the quarter, compared to analysts’ expectations of $16.09 billion. Eli Lilly and Company had a return on equity of 92.72% and a net margin of 25.91%.The firm’s quarterly revenue was up 53.9% on a year-over-year basis. During the same period in the prior year, the business earned $1.18 EPS. Eli Lilly and Company has set its FY 2025 guidance at 23.000-23.700 EPS. Analysts predict that Eli Lilly and Company will post 23.48 EPS for the current fiscal year.

Eli Lilly and Company Dividend Announcement

The business also recently declared a quarterly dividend, which will be paid on Wednesday, December 10th. Stockholders of record on Friday, November 14th will be paid a $1.50 dividend. This represents a $6.00 dividend on an annualized basis and a dividend yield of 0.7%. The ex-dividend date of this dividend is Friday, November 14th. Eli Lilly and Company’s payout ratio is 39.22%.

About Eli Lilly and Company

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.